Replies to post #26508 on Marker Therapeutics Inc (MRKR)

[guydiamond]

It seems to literally be the same technique, except she's targetting only WT1/PRAME/Survivin. Trials TAA-T have going are for Hodgkin's lymphoma/DLCBCL, Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS, and brain tumors.

https://clinicaltrials.gov/ct2/results?cond=&term=TAA-T&cntry=&state=&city=&dist=

Only lymphoma trial is in combination, and all trials are P1, primary completion 2023, with brain tumor primary completion at 2020

I don't see how it wouldn't elicit epitope spreading as it's exactly the same technique. She's only targetting a few different tumors, but using only the same 3 antigens.